金铃芍药散间歇服药法治疗湿热瘀结型慢性盆腔炎的临床研究

doi:10.3760/cma.j.issn.1007-1245.2022.22.013

国际医药卫生导报 ›› 2022, Vol. 28 ›› Issue (22): 3168-3171.DOI: 10.3760/cma.j.issn.1007-1245.2022.22.013

金铃芍药散间歇服药法治疗湿热瘀结型慢性盆腔炎的临床研究

莫小宇谢宜燕崔雪芳

中山陈星海医院妇科，中山　528415

收稿日期:2022-06-18 出版日期:2022-11-15 发布日期:2022-11-18
通讯作者: 莫小宇，Email：994702952@qq.com
基金资助:
中山市医学科研项目（2019A020415）

Clinical study on the treatment of chronic pelvic inflammatory disease of damp-heat stasis type with Jinling Shaoyao powder

Mo Xiaoyu, Xie Yiyan, Cui Xuefang

Department of Gynecology, Zhongshan Chenxinghai Hospital, Zhongshan 528415, China

Received:2022-06-18 Online:2022-11-15 Published:2022-11-18
Contact: Mo Xiaoyu, Email: 994702952@qq.com
Supported by:
Zhongshan Medical Research Project (2019A020415)

摘要/Abstract

摘要： 目的　观察分析金铃芍药散间歇服药法治疗湿热瘀结型慢性盆腔炎（CPID）的临床效果。方法　选择2020年3月至2021年12月期间中山陈星海医院收治的CPID患者129例进行研究，并随机分为3组，各43例。对照A组年龄（34.73±8.79）岁，给予金铃芍药散治疗；对照B组年龄（33.98±8.91）岁，给予中成药“宫炎平片”治疗；观察组年龄（34.89±8.64）岁，给予自拟中药金铃芍药散间歇服药治疗。比较各组临床效果及安全性。采用独立样本t检验、χ²检验。结果　治疗30 d后，观察组综合疗效总有效率为95.35%（41/43）与对照A组［93.02%（40/43）］、对照B组［90.70%（39/43）］比较，差异均无统计学意义（χ²=0.212、0.717，P=0.474、0.801）。治疗30 d后，观察组体征疗效总有效率为97.67%（42/43）与对照A组［95.35%（41/43）］、对照B组［93.02%（40/43）］比较，差异均无统计学意义（χ²=0.345、1.048，P=0.590、0.127）。观察组不良反应发生率为4.65%（2/43）与对照A组［25.58%（11/43）］、对照B组［23.26%（10/43）］比较，差异均有统计学意义（χ²=7.704、6.519，均P<0.001）。结论　金铃芍药散间歇服药法治疗湿热瘀结型CPID与对照A组及对照B组疗法具有同等的临床治疗效果，且相比之下较对照A组及对照B组疗法可以显著减少患者经济负担，提高患者生活质量，节约药品资源，有效降低了临床服用胃肠道不良反应，具有良好的安全性，值得临床大力推广应用。

关键词: 慢性盆腔炎, 金铃芍药散, 间歇服药, 宫炎平片

Abstract: Objective　To observe, evaluate, and analyze the clinical effect of Jinling Shaoyao powder intermittently used in the treatment of chronic pelvic inflammatory disease (CPID) of damp-heat and blood stasis type. Methods　A total of 129 patients with CPID admitted to Zhongshan Chenxinghai Hospital from March 2020 to December 2021 were selected, and were randomly divided into three groups with 43 patients in each group. The control group A was (34.73±8.79) years old and was treated with Jinling Shaoyao powder, the control group B was (33.98±8.91) years old and was treated with Chinese patent medicine "Gongyanping tablets", and the observation group was (34.89±8.64) years old and was treated with Jinling Shaoyao powder, a self-made Chinese medicine, intermittently. The clinical effects and safety of each group were compared. Independent sample t test and χ² test were used. Results　After 30 days of treatment, there were no statistically significant differences in the total effective rate of comprehensive curative effect between the observation group and the control group A and B [95.35% (41/43) vs. 93.02% (40/43), 90.70% (39/43)] (χ²=0.212, 0.717; P=0.474, 0.801). After 30 days of treatment, there were no statistically significant differences in the total effective rate of physical signs between the observation group and the control group A and B [97.67% (42/43) vs. 95.35% (41/43), 93.02% (40/43)] (χ²=0.345, 1.048; P=0.590, 0.127). There were statistically significant differences in the incidence of adverse reactions between the observation group and the control group A and B [4.65% (2/43) vs. 25.58% (11/43), 23.26% (10/43)] (χ²=7.704, 6.519; both P<0.001). Conclusion　Jinling Shaoyao powder used intermittently to treat CPID of damp-heat and blood stasis type has the same clinical treatment effect as the treatment methods of the control group A and B, and compared with the treatment methods of the control group A and B, it can significantly reduce the patients' economic burden, improve their quality of life, save the drug resources, effectively reduce the adverse gastrointestinal effects of clinical use, and has good safety, which is worthy of clinical promotion and application.

Key words: Chronic pelvic inflammatory disease, Jinling Shaoyao powder, Intermittent medication, Gongyanping tablets

莫小宇谢宜燕崔雪芳. 金铃芍药散间歇服药法治疗湿热瘀结型慢性盆腔炎的临床研究[J]. 国际医药卫生导报, 2022, 28(22): 3168-3171.

Mo Xiaoyu, Xie Yiyan, Cui Xuefang. Clinical study on the treatment of chronic pelvic inflammatory disease of damp-heat stasis type with Jinling Shaoyao powder[J]. International Medicine and Health Guidance News, 2022, 28(22): 3168-3171.

参考文献

[1] 姚爱琴. 慢盆方治疗湿热瘀结型慢性盆腔炎临床效果分析[J]. 中外女性健康研究,2020,28(12):119-120.
[2] 张欣,王倩,张朝甲,等. 活血补肾方联合左氧氟沙星治疗湿热瘀结型慢性盆腔炎效果分析[J]. 中华中医药学刊,2021,39(1):42-44.DOI:10.13193/j.issn.1673-7717.2021. 01.012.
[3] 张越,谢文娟,范丽丽,等.红藤煎保留灌肠联合抗生素治疗湿热瘀结型慢性盆腔炎临床研究[J].新中医,2022,54(16):124-128.DOI:10.13457/j.cnki.jncm.2022.16.028.
[4] 于鑫梅. 中西医结合治疗盆腔炎(湿热瘀结型)的临床疗效观察[J]. 中国初级卫生保健,2020,34(6):82-85. DOI:10.3969/j.issn.1001-568X.2020.06.0024.
[5] 李春春,霍艳宁,刘筱茂,等. 银翘红酱汤对湿热瘀结型慢性盆腔炎继发性不孕症疗效研究[J]. 长春中医药大学学报,2020,36(3):529-532.DOI:10.13463/j.cnki.cczyy.2020. 03.035.
[6] 谢幸, 孔北华, 段涛, 等.妇产科学[M].９版.北京:人民卫生出版社,2018.
[7] 张玉珍.中医妇科学[M].北京:中国中医药出版社,2014:317-324.
[8] 郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:243-253.
[9] 夏晓杰,丁宁,王昕. 大黄牡丹汤保留灌肠治疗湿热瘀结型慢性盆腔炎临床观察[J]. 中国中医药现代远程教育,2020,18(22):72-74.DOI:10.3969/j.issn.1672-2779.2020. 22.030.
[10] 拉毛友. 活血补肾方在湿热瘀结型慢性盆腔炎患者治疗中的效果观察[J/CD]. 现代医学与健康研究(电子版),2022,6(3):81-83.
[11] Wang Y, Zhang Y, Zhang Q, et al. Characterization of pelvic and cervical microbiotas from patients with pelvic inflammatory disease[J].J Med Microbiol,2018,67(10):1519-1526.DOI:10.1099/jmm.0.000821.
[12] 张昊悦,赵蓓,王业皇,等. 大黄素通过调节Nrf2/HO-和MAPKs抑制炎症和氧化应激机制研究[J]. 中国免疫学杂志,2021,37(9):1063-1068.DOI:10.3969/j.issn.1000- 484X.2021.09.008.
[13] 祁金金. 红藤煎灌肠液联合常规抗生素治疗慢性盆腔炎临床研究[J]. 新中医,2021,53(13):86-89. DOI:10.13457/j.cnki.jncm.2021.13.021.
[14] 张晨. 慢盆Ⅰ号方联合针刺治疗湿热瘀结型慢性盆腔炎临床研究[J]. 光明中医,2022,37(5):806-808. DOI:10.3969/j.issn.1003-8914.2022.05.026.
[15] 王美霞,滕依丽. 当归芍药散妇科新用举隅[J]. 浙江中医杂志,2018,53(8):610.DOI:10.3969/j.issn.0411-8421.2018. 08.041.
[16] 王华斌. 桂枝茯苓丸辅治慢性盆腔炎疗效及对血液流变学、氧化应激和血清hs-CRP、TGF-β1、GM-CSF、补体C3水平的影响[J]. 中华中医药学刊,2020,38(2):214-217.DOI:10.13193/j.issn.1673-7717.2020.02.053.
[17] 刘亚果. 少腹逐瘀汤联合宫炎平片治疗慢性盆腔炎临床观察[J]. 实用中西医结合临床,2019,19(5):89-91. DOI:10.13638/j.issn.1671-4040.2019.05.046.

金铃芍药散间歇服药法治疗湿热瘀结型慢性盆腔炎的临床研究

Clinical study on the treatment of chronic pelvic inflammatory disease of damp-heat stasis type with Jinling Shaoyao powder

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics